Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.

Pharmaceuticals (Basel) · 2023 · PMC10675154 · PMID 38004437

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

moderately significantno p-value reported

Most recently, Fu and colleagues demonstrated moderately significant AD effects with adjunct intranasal (IN) esketamine but failed to demonstrate an effect for suicidality, the trial’s other primary outcome.

also in 2,178 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.